Seikagaku Reports FY 2Q18 Revenue of ¥7,030, -12% vs. FY 2Q17

Seikagaku continues to be challenged by a sharp decline in Japanese domestic sales due to the impact of National Health Insurance (NHI) drug price reductions implemented in April 2018. The company also faces increased competition and tightening reimbursement requirements on its U.S. hyaluronic acid injectable treatment sales. Sales of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us